Folegatti, P. M., Bittaye, M., Flaxman, A., Lopez, F. R., Bellamy, D., Kupke, A., Mair, C., Makinson, R., Sheridan, J., Rohde, C., Halwe, S., Jeong, Y., Park, Y., Kim, J., Song, M., Boyd, A., Tran, N., Silman, D., Poulton, I., Datoo, M., Marshall, J., Themistocleous, Y., Lawrie, A., Roberts, R., Berrie, E., Becker, S., Lambe, T., Hill, A., Ewer, K., & Gilbert, S. (2020). safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet infectious diseases, 20(7), 816–826. http://access.bl.uk/ark:/81055/vdc_100104125699.0x000012